Darolutamide plus ADT och docetaxel förlänger överlevnaden för patienter med metastaserad hormonkänslig prostatacancer
Results from the Phase III ARASENS trial have shown that the use of the oral androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) and docetaxel significantly increased overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to ADT plus docetaxel.
Läs mer...
